MedPath

Efficacy and Cost Benefit in Filgrastim Biosimilar for Neutropenia in Patients Receiving Chemotherapy: A Single-center, Non-randomized Cohort Study

Not Applicable
Recruiting
Conditions
Gynecologic cancer
Registration Number
JPRN-UMIN000019110
Lead Sponsor
Oita University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Female
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1) The patients with the bone marrow infiltration 2) Is the patients with hypersensitivity to Patient 3) G-CSF preparation which received radiotherapy within four weeks before registration at chemotherapy initiation 4) The patients who judged that a chief physician was inappropriate

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
eutropenic (neutrophil count <1,000/mm3) period in each treatment cycle
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath